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Abstract 
Chromosomal abnormalities are increasingly used to risk stratify adults with ALL. 
Published data describing the age-specific incidence of chromosomal abnormalities and 
their prognostic relevance is largely derived from clinical trials. Trials frequently have 
age restrictions and low recruitment rates. Thus we investigated these factors in a 
population-based cohort of 349 patients diagnosed over 19 years in the North of the UK. 
The incidence of most chromosomal abnormalities varied significantly with age. The 
incidence of t(9;22)(q34;q11) increased in each successive decade, up to 24% among 
40-49 year olds. Thereafter the incidence reached a plateau. t(4;11)(q21;q23) and 
t(1;19)(q23;p13) were rare among patients aged over 60 years. In contrast, 
t(8;14)(q24;q32) and t(14;18)(q32;q21) increased with age. High hyperdiploidy 
occurred in 13% of patients <20 years but in only 5% of older patients. The incidence of 
low hypodiploidy / near–triploidy (HoTr) and complex karyotype increased with age from 
4% (15-29 years) to 16% (60+ years). Overall survival varied significantly by age and 
cytogenetics. Older patients and those with t(9;22), t(4;11), Ho-Tr or complex karyotype 
had a significantly inferior outcome. These population-based results demonstrate the 
cytogenetic heterogeneity of adult ALL. These data will inform service planning and the 
design of new age-focussed clinical trials. 
Introduction 
Recurrent and clonal chromosomal abnormalities in the leukaemic cells of patients with 
acute lymphoblastic leukaemia (ALL) are the hallmark of the disease and are now 
routinely used in the paediatric setting to assist patient management, particularly in 
terms of diagnosis, disease monitoring, prognosis and risk stratification.1 The clinical 
utility of cytogenetics in adult ALL is an emerging topic and more studies are urgently 
required.2,3 To date the majority of cytogenetic studies (paediatric and adult) have been 
based on patients enrolled to local, national or international clinical trials. In paediatric 
ALL these studies can be considered representative because recruitment rates in this age 
group are very high. However, trial recruitment is much lower among adolescents and 
adults.4 Moreover, adults aged over 60 years are rarely eligible for clinical trials.5,6
Population-based studies of adult ALL are rare. The lack of studies describing the age-
specific incidence of chromosomal abnormalities and their prognostic relevance makes 
planning services and clinical trials difficult. There are several current issues which would 
benefit significantly from such data: (1) The treatment of adolescents and young adults 
is controversial with many clinical trial groups opting to treat them on paediatric 
protocols.7-10 However, the distinct genetic profile of these patients has not been taken 
into consideration.11 (2) There is renewed interest in developing treatment protocols for 
older (more than 60 years old) adults12; (3) Recent studies have demonstrated that 
cytogenetics is highly predictive of outcome in adult ALL but the effectiveness of these 
markers has not been tested outside clinical trials.2,3 In this report we present 
population-based cytogenetic, clinical and outcome data from 349 adult ALL patients 
diagnosed over a 19 year period in a single region of the North of England. 
Patients and Methods 
Study Area and Population data 
The study area comprised the region served by the NHS North East Strategic Health 
Authority during this period. The total population of this region is 3.1 million and includes 
2.5 million people aged 15 years old or more (Office for National Statistics - 
http://www.statistics.gov.uk/). Age-specific incidence rates were calculated using the 
average of the population determined by the 1991 and 2001 UK censuses (Office for 
National Statistics). Since October 1982, the consultant haematologists in this region 
have collaborated to keep a register of all newly diagnosed patients with ALL.5 Ethical 
approval to conduct this audit was granted by the relevant treatment centres.  
Diagnosis 
All patients diagnosed between 1st January 1983 and 31st December 2001 with ALL and 
aged 15 years or more were included in this study. In all cases, the diagnosis was 
confirmed by morphology and appropriate cytochemical staining. Immunophenotyping 
was performed where possible using standard methodologies and cases were 
retrospectively classified into one of five subgroups (pro-B, BCP-ALL, mature-B, T-ALL 
and biphenotypic) using the original immunological classification. 
Cytogenetics 
Cytogenetic studies were performed at one of three laboratories in the region (see 
acknowledgements) but collated by the NHS Northern Genetics Service. Analysis was 
performed on pre-treatment bone marrow or peripheral blood samples using standard G-
banding techniques. Screening for the major chromosomal translocations [t(9;22)/BCR-
ABL1, MLL/11q23 rearrangements] using fluorescence in situ hybridisation (FISH) and/or 
Reverse-transcriptase Polymerase Chain Reaction (RT-PCR) assays became routine 
practice at the beginning of 1997. Chromosomal abnormalities were defined and 
recorded according to the International System for Human Cytogenetic Nomenclature 
(ISCN).13 None of the patients presented in this report were included in the previous 
cytogenetic study of patients treated on MRC UKALLXII/ECOG2993.2
Treatment 
Patients under the age of 55 years with ALL (B-cell precursor, T-cell and mature-B) or 
acute biphenotypic leukaemia, who were treated with curative intent,  were mostly 
treated according to regional North East ALL protocols (NE-ALL III-VI).14,15 Occasionally 
patients were treated according to, but not registered on, national  protocols (UKALLXII, 
UKALLXA)16,17. Acute biphenotypic leukaemia was defined as terminal deoxynucleotidyl 
transferase (TdT) positive patients who also expressed some myeloid antigens. In this 
era TdT positivity was considered the key marker indicating involvement of the lymphoid 
lineage and hence ALL therapy. The multi-agent protocol NE-ALL III15 was introduced in 
1982 and correlates with the start of this study. In 1984, routine standard maintenance 
was stopped for patients under 55 years and instead these patients were offered, in first 
remission, an allogeneic transplant or, in the absence of a family donor, an autologous 
transplant.14 Patients under 45 years underwent a preconditioning regimen of 
cyclophosphamide (60mg/Kg) and total body irradiation (1200cGy) and those aged 45-
55 years received melphalan (3mg/Kg), total body irradiation (1050cGy) and non-
cryopreserved marrow rescue. Between 1988-1994 (NE-ALL IV–V), idarubicin replaced 
adriamycin in induction because of improved penetration into the CNS, and prednisolone 
was replaced by dexamethasone. Cranial irradiation was used throughout NE-ALL III-V 
unless the patient received irradiation as part of their conditioning for a transplant. The 
last NE-ALL protocol in the series (NE-ALL VI) started in 1994. Cranial irradiation was 
abandoned and replaced by a consolidation phase in which two courses of high dose 
methotrexate were alternated with two courses of high dose iphosphamide, epirubicin 
and etoposide (IVE). The transplant policy in NE-ALL VI was the same as NE-ALL IV-V 
and applied consistently until 2001. Patients aged 55 years or more were treated as 
previously described.5
Statistics
Categorical variables were compared using the chi-square or Fisher exact tests. The 
Mann Whitney rank test was used to compare the age distribution of different 
cytogenetic subgroups. Complete remission (CR) was defined morphologically as fewer 
than 5% blasts in the bone marrow, immunologically as TdT/CD10 negativity (pre-1995) 
or by molecular assessment of immunoglobulin and T cell gene rearrangements (post 
1995). Survival analysis was restricted to those patients who were treated using an 
intention to cure protocol (n=250). Patients who received only palliative care, those who 
presented with advanced organ failure and those who died before a CR could be 
assessed were deemed not to have received treatment with curative intent (n=99) and, 
therefore, were not included in the survival analysis. Overall survival (OS) was defined 
as the time from diagnosis to death or last contact. Survival estimates, life tables and 
curves were constructed by means of the Kaplan-Meier method. The variables age and 
cytogenetic risk group were initially analysed in isolation using univariate Cox regression 
models. Multivariate Cox regression on these variables was then performed via a 
stepwise modelling process based on the difference between successive models 
calculated using the log likelihood. At this stage of analysis there was a further reduction 
of the number of patients analysed due to missing cytogenetics (n=73), dates (n=13) or 
because of statistical concerns over their excessive influence on the model (n=2). Thus a 
total of 162 patients were included in the multivariate model. Due to the exploratory 
nature of this analysis all calculations were considered at the 5% significance level. 
Results  
Descriptive epidemiology  
A total of 349 adults aged 15 years or more were diagnosed with ALL during the study 
period. Although the number of patients diagnosed each year varied there was no trend 
towards either an increase or decrease in the incidence of the disease during the study 
period (Figure 1). The incidence of ALL varied by age and a bimodal distribution was 
observed with the younger (15-19) and older adults (70+ years) having the greatest 
incidence (Figure 2). Approximately one third of the patients were aged 60 years or 
more (Table 1).  
Overall there were more males than females (1.2M:1F) but this ratio varied significantly 
with age (p<0.03) (Table 1, Figure 2). The excess of males was confined to younger 
adults where the ratio was 1.8M:1F. In addition, the excess of males was more 
pronounced in among T-ALL patients where a ratio of 2.2M:1F was observed. T-ALL 
patients were also younger (see below). Figure 2 shows the age-specific incidence of ALL 
for males and females separately, demonstrating that the change in the sex ratio with 
increasing age is not simply a function of the increased life expectancy enjoyed by 
females. 
The majority of patients had a B-lineage ALL (240, 81%), while 42 (14%) had T-ALL and 
15 (5%) were described as biphenotypic (see Methods). However, this distribution 
differed significantly with age (p<0.001) (Table 1). Patients with mature-B ALL, which 
comprised 11% of patients overall, were significantly older - median age 63 years 
(interquartile range (IQR) – 53 to 71 years) versus 42 years (IQR 23 to 66 years) 
(p=0.0001). In contrast, T-ALL patients were significantly younger - median age 25 
years (IQR 19 to 42 years) versus 48 years (IQR 26 to 69 years) (p=0.0001).  
White cell count (WCC) was strongly correlated with immunophenotype. Patients with T-
ALL were significantly more likely to have a WCC of >50x109/L compared to B-lineage 
patients: 17/42 (40%) versus 47/247 (19%), p=0.001. Given that T-ALL were also 
significantly younger (see above), this translated into older patients appearing to have a 
lower WCC (Table 1). However, no such effect was seen if the T-ALL patients were 
excluded (data not shown).  
Diagnostic cytogenetic analysis 
Cytogenetic analysis was attempted in 292/349 (84%) patients but was significantly 
more prevalent after 1993: 160/171 (94%) versus 132/178 (74%) (p<0.001) (Table 1 & 
Figure 1). This was true across all age groups (data not shown). A total of 236 (81%) 
had a successful cytogenetic result and a clonal chromosomal abnormality was detected 
in 173 (73%) patients. These rates did not vary during the study period (p>0.05) or by 
age (p>0.05). Overall cytogenetics revealed a normal karyotype in 63 (27%) patients 
but this was more prevalent among T-ALL patients (14/30, 47%) compared to B lineage 
patients (38/176, 22%) (p=0.006). As T-ALL patients are younger this explains the 
higher incidence of normal karyotype in adolescents (15-19 years).  
The most prevalent specific chromosomal abnormality was the Philadelphia chromosome 
[t(9;22)(q34;q11), BCR-ABL1] which was present in 36 (15%) patients. There was no 
difference in the incidence before and after the introduction of routine FISH/RT-PCR at 
beginning of 1997: 24/158 (15%) versus 12/92 (13%) (p>0.1). The prevalence 
increased with age up to, but not beyond, the fourth decade: 15-19 years 2/42 (5%), 
20-29 years 4/35 (11%), 30-39 years 4/26 (15%), 40-49 years 7/29 (24%), 50-59 
years 5/24 (21%), 60-69 years 8/38 (21%), 70-79 years 4/30 (13%), 80+ years 2/12 
(17%). Thus while there was a significant difference in the incidence of t(9;22) between 
patients aged 15-30 years (7%) and those aged over 30 years (24%) (p=0.02), there 
was no difference between those aged 30-60 years (22%) and over 60 years (16%) 
(p=0.4). The majority of t(9;22) patients had BCP-ALL (32/35, 91%) but 3 patients were 
described as having a biphenotypic immunophenotype. Just over half the t(9;22) 
patients (19/34, 56%) had a WCC less than 50x109/L while the remaining 15 patients 
had a WCC of more than 50x109/L including 10 patients with a WCC of more than 
100x109/L.  
Other established chromosomal translocations: t(4;11), t(1;19), t(8;14), t(14;18); each 
occurred in less than 10% of patients but showed strong correlations with age. Both 
t(4;11) and t(1;19) occurred more often in younger adults and t(8;14) and t(14;18) in 
older adults (60+ years) (Table 2). The two ploidy subgroups, high hyperdiploidy (51-65 
chromosomes, HeH) and low hypodiploidy/near triploidy (30-39 & 60-78 chromosomes, 
HoTr), were observed in 7% and 3% of patients, respectively. None of these patients 
had T-ALL or Mature-B ALL and they were associated with younger and older age, 
respectively (Table 2). Patients without one of the aforementioned established 
chromosomal abnormalities or tetraploidy were classified as having a complex 
karyotype, if five or more clonal chromosomal abnormalities were observed. This 
subgroup accounted for 7% of patients overall but was more prevalent among patients 
over 60 years old. Collectively, Philadelphia negative patients with high risk 
cytogenetics; defined as t(4;11), t(8;14), HoTr and complex karyotype2, were 
significantly more prevalent among patients over the age of 60 years: 24/66 (36%) 
versus 25/134 (19%) (p=0.006). 
The most prevalent cytogenetic subgroups were the other abnormal group and those 
with a normal karyotype which together accounted for more than 50% of patients with 
successful cytogenetics. Among the 59 patients classified as “other abnormal” some 
known chromosomal abnormalities were observed but were too infrequent to be 
analysed separately. Examples include, t(10;14)(q24;q11) (n=2) and t(11;14)(p13;q11) 
(n=1). Known secondary chromosomal abnormalities, such as deletions of 6q (n=9) and 
9p (n=6), were also observed both in combination with established abnormalities and 
within the “other abnormal” and complex karyotype groups but at too low a frequency to 
be analysed separately. 
Outcome and prognostic relevance of chromosomal abnormalities  
Among the 349 patients in this cohort, 250 (72%) were treated with curative intent. This 
included 211/225 (94%) patients under the age of 60 years but only 39/124 (31%) of 
those over 60 years old. Only the outcome of patients who were actively treated have 
been considered in this section. A complete remission (CR) was achieved by 194/247 
(78%) patients who were actively treated. However, this rate varied by age and 
cytogenetics (Table 1 and 2). Significantly fewer patients over the age of 60 years 
achieved a CR compared to those under 60 years: 20/39 (51%) versus 174/208 (84%) 
(p<0.001). In addition, fewer patients with t(9;22) or other high risk cytogenetics
achieved a CR (Tables 1 and 2). 
Among the 250 actively treated patients, 100 (40%) received a bone marrow transplant: 
autologous (n=66), allogeneic (n=29) or matched unrelated (MUD) (n=6). All but six of 
the transplants were performed in first CR. None of the patients over the age of 60 years 
received a transplant compared with 59/115 (51%) 15-29 year olds and 41/110 (37%) 
30-60 year olds.  The remaining 99 patients received chemotherapy alone.  
Given the duration of the study and the heterogeneity of treatments received, we have 
only considered overall survival. Recent data suggest that in adult ALL outcome after 
relapse is extremely poor18; hence this is a suitable endpoint to be considered by this 
study. The median follow-up time for this cohort was 6.25 years. The 5 year overall 
survival (OS) rate for the whole cohort was 30% (95% C.I. 24-36%). However, this 
figure varied considerably by age and cytogenetics (Tables 1 and 2, Figures 3 and 4). 
Estimates of the 5 year OS rates by each decade were as follows: 15-19 years 47% 
(95% CI 33-61%); 20-29 years 43% (95% CI 29-57%); 30-39 years 16% (6-32%); 40-
49 years 20% (8-36%); 50-59 years 19% (7-36%); 60+ years 12% (3-27%). Older 
patients and those with poor risk cytogenetics, as defined by the MRC UKALLXII / ECOG 
2993 trial, had a significantly worse outcome (Tables 1 and 2, Figures 3 and 4). We have 
already demonstrated (Tables 1 & 2) that cytogenetics and age are closely related. The 
frequency of poor risk cytogenetics (e.g. t(9;22), t(8;14), HoTr and complex karyotype) 
was higher among older patients and fewer older patients had HeH. There was little 
change in the outcome of patients during the study period. Although there was a 
marginally increase in the OS at 5 years for patients aged 30 years and above the 
difference was not statistically significant (data not shown). 
In order to determine whether the adverse affect of cytogenetics was independent of age 
we performed multivariate analysis. Due to the relatively small number of patients with 
both cytogenetic and outcome data (n=162), we were able to consider only three 
cytogenetic risk groups: t(9;22) – all patients with t(9;22)/BCR-ABL; poor – patients 
with t(4;11), t(8;14), t(14;18), HoTr and complex karyotype; standard – all other 
patients. A Cox proportional hazards model containing just age and cytogenetic risk 
group indicated a statistical interaction between age and cytogenetics. Adding an 
interaction term to the model revealed that both age and cytogenetics were contributing 
significantly to outcome. Patients with t(9;22) had a 12.5 fold increase risk of dying 
(hazard ratio 12.50, 95% C.I. 2.69-58.07, p=0.001) while those with poor risk 
cytogenetics had a 3.5 fold increased risk (hazard ratio 3.47, 95% C.I. 1.45-8.37, 
p=0.007), both in comparison to patients with standard risk cytogenetics. The statistical 
interaction between cytogenetics and age indicates that the effect of cytogenetics might 
not be the same at all ages. However, given the size of the cohort, the relatively crude 
measure of outcome used and the heterogeneity of treatment it was not possible to 
investigate this further.  
Incidence of major chromosomal abnormalities in this study compared to previously 
published data from clinical trials 
We compared the incidence of the major chromosomal abnormalities in this study to that 
observed in six major clinical trials (Table 3). As most clinical trials impose age limits on 
potential subjects we restricted the comparison to those patients in this study aged 
between 15 and 59 year old. Aside from the variation in the incidence of normal 
karyotype and t(9;22) there was little difference. However, it should be noted that 
several of the abnormalities were only classified in a few studies. The overall frequency 
of t(9;22) in this population-based study was 15% which compares well with that 
reported by the two recent UK based trials: MRC UKALLXA17 (11%) and UKALLXII2
(16%). In contrast, the overall frequency of t(9;22) ALL reported by other trial based 
studies is much higher: ECOG29932 (25%); GMALL19 (36%); GIMEMA049620 (23-31%); 
GFCH21 (29%); SWOG94003 (27%); CALGB22 (26%). (Table 4). These differences are 
likely to be due to a combination of factors, including the age profile of the underlying 
populations, recruitment bias and detection method. Although there are exceptions, 
generally studies with a lower frequency of t(9;22) comprise a greater proportion of 
younger patients and vice versa. 
Discussion 
We have reported the largest population-based cytogenetic study of adults with ALL. The 
overall incidence rate and pattern of incidence by age and gender was similar to that 
seen in other areas of the UK.23 This was an appropriate region in which to examine the 
relationship between age and cytogenetics. Firstly, there was no overlap with the 
previous publication based on the MRC UKALLXII/ECOG 2993 cohort from which we 
derived our cytogenetic risk criteria. Although some patients (<10%) were treated 
according to the same protocol, they were not officially registered on the trial. Secondly, 
the age-specific OS rates observed in this region were similar to that observed in other 
regions of the UK.4,24 The results clearly demonstrate that the incidence of cytogenetic 
and immunophenotypic subgroups varies markedly with the age. While it is known that 
the incidence of specific chromosomal abnormalities differs between children and adults, 
the age-specific frequency of such lesions within adult ALL, especially among those over 
60 years old, was hitherto unknown or poorly studied.  
The results of recent clinical trials of adult ALL have highlighted the importance of 
cytogenetics in predicting the risk of relapse.2,3 Such studies support the development of 
cytogenetic-based risk stratification of adults in future trials. One of the limitations of 
these studies was that they were based on a relatively small proportion of the total 
available patients; as most adult patients with ALL are not recruited to clinical trials. One 
of the key questions in this field of research is whether the specific chromosomal 
abnormalities identified as being indicators of poor outcome in the MRC 
UKALLXII/ECOG2993 trial retained their prognostic relevance outside the context of a 
clinical trial. Our analyses suggest that both age and cytogenetics are important 
predictors of outcome in adult ALL. The relatively small number of patients with 
individual poor risk chromosomal abnormalities prevented an in depth analysis. Overall 
the data in this study support our previous observations that patients with t(4;11), 
t(8;14), HoTr and complex karyotype have an inferior outcome. However, it should be 
noted that (a) there was evidence to suggest that the effect of cytogenetics varied with 
age; and (b) the treatment received by this cohort was over a 19 year period and hence 
heterogeneous. 
We confirmed the findings of Burmeister et al (2008)19 who reported that the frequency 
of t(9;22)/BCR-ABL positive adult ALL does not continue to increase beyond the fourth 
decade of life. These results are in contrast to the popularly held belief that the incidence 
of t(9;22) positive ALL continues to rise with age. The overall frequency of t(9;22) ALL in 
this study and other UK trial studies was considerably lower than that observed in series 
from other countries (Table 4). Although differences in the age profile of the underlying 
populations are likely to explain some of the variation, the picture appears more 
complicated and may reflect geographical heterogeneity.25 Patients with t(9;22) are now 
usually treated with imatinib mesylate or another tyrosine kinase inhibitor in combination 
with multi-agent chemotherapy. These data indicate that such therapy will be suitable 
for a smaller fraction of patients aged more than 60 years than had been anticipated.  
Even though this study is the largest and most comprehensive of its kind to date, it does 
have its limitations. Firstly, the number of patients was still quite small and hence the 
number with specific chromosomal abnormalities was too few to undertake detailed 
survival analysis. Secondly, rarer and secondary chromosomal abnormalities could not 
be considered. Thirdly, even though most treatment occurred in a single centre and with 
the same ethos, this study spanned nearly 20 years. Finally, the global genomic analysis 
of childhood ALL has revealed a wide spectrum of copy number alterations (CNA) beyond 
the resolution of cytogenetics.26 Many are microdeletions targeting B-cell development 
genes (e.g. IKZF1, PAX5, VpreB1 etc) and most correlate with established cytogenetic 
subgroups.26,27 Initial investigations in adult ALL suggest that similar CNAs are present.28
Given that approximately a half of the patients in this study could not be assigned to a 
clinically relevant cytogenetic subgroup future studies will need to incorporate high 
quality cytogenetic, FISH and genomic data in order to fully characterise patients. 
Moreover, such studies will need to be population based in order to efficiently plan 
services, design clinical trials and fully utilise the prognostic relevance of genetic 
markers.
Several recent studies have reported that adolescents and young adults (AYA) have a 
better outcome when treated on paediatric protocols.7-10 Several groups worldwide are 
now treating AYA up to the age of 29 years on paediatric protocols.10,29 Since AYA are 
much less likely to enrol on clinical trials than children,4 this study is the most 
informative to date as to their cytogenetic profile. Interestingly it is markedly different 
from both the classical paediatric profile and the adult profile.1 The frequency of HeH is 
much lower than seen among childhood cohorts (13% v ~30%) whereas the frequency 
of t(9;22) and other “adult” cytogenetic abnormalities such as HoTr and complex 
karyotype is much lower. Unfortunately, our patients have not been screened for ETV6-
RUNX1 fusion. However, our previous study suggested that this would be present at a 
much lower frequency than in childhood ALL.30 The frequency of T-ALL is this age group 
is noteworthy; at 25% it is higher than in both childhood ALL and adults aged over 30 
years.
One of the major strengths of this study is the unselected nature of the cohort and we 
were able to estimate the incidence of ALL at all ages, and by gender and year of 
diagnosis. There was no evidence to suggest that the incidence of this disease was 
increasing with time. However, the observation that the incidence continues to increase 
with age among both males and females suggests that the absolute number of patients 
is likely to increase in the context of an aging population. Thus “elderly” ALL is likely to 
become an increasing health burden over the next two decades, especially as other have 
reported that there has been no improvement in outcome for these patients.6 Hence new 
clinical trials targeting this age group are urgently required. 
We were able to examine the cytogenetic profile of 124 patients aged over 60 years. 
This age group is largely under-reported due to the upper age limit of most clinical trials 
being 55-65 years. Although diagnostic cytogenetic investigations were less frequently 
requested in this age group, when they were attempted the success and abnormality 
rates were similar, if not better, compared to younger patients. These results suggest 
that pre-treatment cytogenetic analysis for adults with ALL should be performed 
irrespective of age. Interestingly the biological and cytogenetic profile of these “older” 
patients was quite different compared to younger patients. Mature-B ALL [plus 
t(8;14)/t(14;18)] was more prevalent while T-ALL was markedly less prevalent. Such 
information is important for planning services and designing clinical trials. Patients with 
mature-B ALL will now routinely receive treatment on lymphoma protocols.31 The 
translocations, t(4;11) and t(1;19), were rare among patients over 60 years old as was 
HeH. In contrast, the recently established poor risk groups – HoTr and complex 
karyotype – were more prevalent in this older subgroup.  
As older adults (60 years plus) were less likely to receive curative treatment, the 
proportion of such patients included in the multivariate model was lower. Hence it is 
difficult to assess the effect of cytogenetics in this age group. Recent data from SEER 
showed that this age group was the only one that has not benefited from recent 
improvements in survival.6 Therefore, further investigation into the cytogenetics of this 
age group is urgently required in order to maximum the usefulness of future clinical 
trials aimed at this age group.  
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Table!1:!Demographic,!clinical!and!cytogenetic!features!of!349!adults!with!acute!lymphoblastic!leukaemia!(ALL).!
†!Information!only!available!for!320!patients.!
! ! 15"!29! 30"59! 60+! Total!
Total!(n)! ! 115! 110! 124! 349!
Gender! Sex!Ratio!M:F! 1:0.6! 1:1.1! 1:1.1! 1:0.9!
WCC†! <10! 55!(48%)! 40!(38%)! 42!(41%)! 137! (43%)!
! 10!"!49.9! 35!(30%)! 33!(32%)! 46!(45%)! 114! (36%)!
! 50+! 24!(21%)! 31!(30%)! 14!(14%)! 69! (21%)!
Immunophenotype*! Pro"B! 7!! (7%)! 15!(15%)! 11!(12%)! 33! (10%)!
! B"Cell!Precursor! 71!(68%)! 60!(59%)! 44!(49%)! 175! (55%)!
! Mature!B! 1!! (<1%)! 10!(10%)! 21!(23%)! 32! (10%)!
! T"ALL! 26!(25%)! 11!(11%)! 5!! (6%)! 42! (13%)!
! Biphenotypic! 0! 6!(6%)! 9!! (10%)! 15! (5%)!
Cytogenetic!! Attempted! 98!(85%)! 100!(91%)! 94!(73%)! 292!(84%)!
Investigations! !!!!!Successful! !!!77!(79%)! !!!79!(79%)! !!!80!(85%)! !!!236!(81%)!
! !!!!!!!!!Normal! !!!!!25!(32%)! !!!!!19!(24%)! !!!!!18!(23%)! ! 62!(26%)!
! !!!!!!!!!Abnormal! !!!!!52!(68%)! !!!!!60!(76%)! !!!!!62!(77%)! ! 174!(74%)!
Cytogenetic! Attempted! 44!(76%)! 51!(86%)! 37!(61%)! 132!(74%)!
Investigations! !!!!!Successful! !!32!(73%)! !!38!(75%)! !!30!(81%)! !!100!(76%)!
(Pre!Jan!1993)! !!!!!!!!!Normal! !!!12!(38%)! !!!8!(21%)! !!!!11!(37%)! ! 31!(31%)!
! !!!!!!!!!Abnormal! !!!20!(63%)! !!!30!(79%)! !!!!19!(63%)! ! 69!(69%)!
Cytogenetic! Attempted! 54!(95%)! 49!(96%)! 57!(90%)! 160!(94%)!
Investigations! !!!!!Successful! !!!45!(88%)! !!!41!(84%)! !!!50!(88%)! !!!136!(85%)!
(Post!Jan!1993)! !!!!!!!!!Normal! !!!!!13!(29%)! !!!!!11!(27%)! !!!!!!!7!(14%)! ! 31!(23%)!
! !!!!!!!!!Abnormal! !!!!!32!(71%)! !!!!!30!(73%)! !!!!!43!(86%)! ! 105!(77%)!
Chromosomal! Classifications! ! ! ! !
Abnormality
e
! !!!Total! 77! 79! 80! 236!
! !!!!!t(9;22)(q34;q11)! 6!(8%)! 16!(20%)! 14!(18%)! 36!! (15%)!
! !!!!!t(4;11)(q21;q23)! 4!(5%)! 5!(6%)! 1!(1%)! 10!! (4%)!
! !!!!!t(1;19)(q23;p13)! 4!(5%)! 2!(3%)! 0! 6!! (3%)!
! !!!!!t(8;14)(q24;q32)! 0! 7!(9%)! 10!(13%)! 17!! (7%)!
! !!!!!t(14;18)(q32;q21)
‡
! 0! 2!(3%)! 8!(10%)! 10!! (4%)!
! !!!!!HeH
a
! 10!(13%)! 4!(5%)! 3!(4%)! 17!! (7%)!
! !!!!!HoTr
b
! 1!(1%)! 2!(3%)! 4!(5%)! 7!! (3%)!
! !!!!!Complex
c
! 2!(3%)! 4!(6%)! 9!(11%)! 15!! (7%)!
! !!!!!Other! 25!(32%)! 18!(23%)! 16!(20%)! 59!! (25%)!
! !!!!!Normal
d
! 25!(32%)! 19!(24%)! 18!(23%)! 62!! (26%)!
CR!rate**!
!
! 89%!
(99/111)!
77%!
(75/97)!
51%!
(20/39)!
79%!
(194/247)!
OS!Estimate!–!5!yrs***!
95%!CI!
! 45%!
35!–!55%!
19%!
11!–!28%!
12%!
4!–!27%!
30%!
24"36%!
*!Information!only!available!for!297!patients.!
‡
!This!karyotype!was!expressed!in!conjunction!with!the!t(8;14)!in!3!patients.!
**!CR!only!available!for!247!patients.!
***!OS!rate!available!for!234!patients!due!to!missing!data.!
a
!High!hyperdiploidy!(51"65!chromosomes).!
b
!Low!hyperdiploidy!(30"39!chromosomes)!/!Near!triploidy!(60"78!chromosomes).!
c
!Complex!karyotype!defined!as!five!or!more!chromosomal!abnormalities!in!the!absence!of!an!established!
cytogenetic!subgroup.!
d
!20!or!more!normal!metaphases!in!the!absence!of!any!clonal!chromosomal!abnormality.!
e
!Mutually!exclusive.
T
a
b
le
!2
:!
D
e
m
o
g
ra
p
h
ic
,!
cl
in
ic
a
l!
a
n
d
!s
u
rv
iv
a
l!
d
a
ta
!f
o
r!
3
4
9
!a
d
u
lt
s!
w
it
h
!a
cu
te
!l
y
m
p
h
o
b
la
st
ic
!l
e
u
k
a
e
m
ia
!(
A
LL
).
!
! !
T
o
ta
l!
S
e
x
!
R
a
ti
o
!
M
:F
!
A
g
e
!
W
C
C
†
!
O
u
tc
o
m
e
*
!
T
re
a
te
d
!
C
R
!r
a
te
*
*
!
D
e
a
th
s*
*
*
!
O
v
e
ra
ll
!S
u
rv
iv
a
l!
a
t!
5
y
rs
*
*
*
*
!!
M
e
a
n
%
>
6
0
!
y
rs
!
M
e
d
ia
n
!
%
>
5
0
!
O
v
e
ra
ll
!
S
u
rv
iv
a
l!
9
5
%
!C
I!
T
o
ta
l!
(F
u
ll
!D
a
ta
se
t)
!
3
4
9
!
1
:0
.9
!
4
6
.4
!
3
6
%
!
1
3
.6
!
2
0
%
!
2
5
0
!
!
7
2
%
!
1
9
4
!
7
9
%
!
1
7
7
!
7
3
%
!
3
0
%
!
(2
4
–
3
6
%
)!
S
u
cc
e
ss
fu
l!
C
y
to
g
e
n
e
ti
cs
!
!
!
!
!
!
!
!
!
!
!
!
T
o
ta
l!
2
3
6
!
1
:0
.8
!
4
5
.4
!
3
4
%
!
1
4
.6
!
2
0
%
!
1
7
7
!
7
5
%
!
1
3
3
!
7
5
%
!
1
2
6
!
7
1
%
!
2
9
%
!
(2
2
!–
!3
7
%
)!
t(
9
;2
2
)(
q
3
4
;q
1
1
)!
3
6
!!
(1
5
%
)!
1
:0
.6
!
5
0
.6
!
3
9
%
!
3
0
.1
!
4
2
%
!
2
6
!
7
2
%
!
1
7
!
6
5
%
!
2
4
!
!
9
2
%
!
9
%
!
(2
!–
!2
6
%
)!
t(
4
;1
1
)(
q
2
1
;q
2
3
)!
1
0
!!
(4
%
)!
1
:1
.5
!
3
9
.1
!
1
0
%
!
4
3
.6
!
5
0
%
!
9
!
9
0
%
!
7
!
7
8
%
!
6
!
!
6
7
%
!
3
3
%
!a
t!
3
y
rs
!
(8
"6
2
%
)!
t(
1
;1
9
)(
q
2
3
;p
1
3
)!
6
!!
(3
%
)!
1
:5
!
3
3
.2
!
!
2
1
.5
!
1
6
%
!
6
!
1
0
0
%
!
6
!
!
1
0
0
%
!
3
!
!
5
0
%
!
6
0
%
!
(1
3
!–
!8
8
%
)!
t(
8
;1
4
)(
q
2
4
;q
3
2
)!
1
7
!!
(7
%
)!
1
:0
.9
!
6
0
.8
!
5
9
%
!
1
5
.7
!
6
%
!
1
0
!
5
9
%
!
4
!
4
4
%
!
8
!
8
0
%
!
2
0
%
!
(3
!–
!4
8
%
)!
t(
1
4
;1
8
)(
q
3
2
;q
2
1
)‡
!
1
0
!!
(4
%
)!
1
:0
.8
!
6
0
.0
!
6
7
%
!
2
0
.0
!
1
6
%
!
5
!
!5
0
%
!
2
!
!
4
0
%
!
4
!
!
8
0
%
!
3
3
%
!a
t!
1
y
r!
(1
"7
7
%
)!
H
e
H
a
!
1
7
!!
(7
%
)!
1
:0
.5
!
3
3
.9
!
1
8
%
!
3
.1
!
6
%
!
1
5
!
!8
8
%
!
1
5
!
!
1
0
0
%
!
5
!
!
3
6
%
!
7
7
%
!
(4
5
!–
!9
2
%
)!
H
o
T
rb
!
7
!!
(3
%
)!
1
:1
.3
!
5
5
.1
!
8
6
%
!
2
.6
!
"!
6
!
8
6
%
!
4
!
6
7
%
!
6
!
1
0
0
%
!
0
%
!
"!
C
o
m
p
le
xc
!
1
5
!!
(7
%
)!
1
:0
.5
!
5
8
.9
!
6
0
%
!
1
3
.0
!
"!
5
!
3
3
%
!
4
!
8
0
%
!
4
!
!
8
0
%
!
2
0
%
!
(1
!–
!5
8
%
)!
O
th
e
r!
5
9
!!
(2
5
%
)!
1
:0
.8
!
4
2
.2
!
2
9
%
!
1
6
.3
!
2
4
%
!
4
8
!
8
5
%
!
3
9
!
8
1
%
!
3
4
!
!
7
6
%
!
2
7
%
!
(1
4
!"
!4
1
%
)!
N
o
rm
a
ld
!
6
2
!!
(2
6
%
)!
1
:0
.7
!
4
0
.8
!
2
9
%
!
1
0
.0
!
1
6
%
!
4
9
!
7
9
%
!
3
5
!
7
1
%
!
3
4
!
!
6
9
%
!
3
2
%
!
(1
8
"!
4
6
%
)!
C
y
to
g
e
n
e
ti
c!
R
is
k
!
G
ro
u
p
!
!
!
!
!
!
!
!
!
!
!
!
t(
9
;2
2
)!
3
6
!
1
5
%
!
1
:0
.6
!
5
0
.6
!
3
9
%
!
3
0
.1
!
4
2
%
!
2
6
!
7
2
%
!
1
7
!
6
5
%
!
2
4
!
!
9
2
%
!
9
%
!
(2
"2
6
%
)!
P
o
o
r!
5
6
!
2
4
%
!
1
:1
.3
!
5
5
.8
!
5
2
%
!
1
5
.2
!
1
3
%
!
3
3
!
5
9
%
!
2
1
!
6
6
%
!
2
6
!
!
7
9
%
!
1
9
%
!
(7
"3
6
%
)!
S
ta
n
d
a
rd
!
1
4
4
!
6
1
%
!
1
:0
.8
!
4
0
.0
!
2
6
%
!
1
1
.0
!
1
8
%
!
1
1
8
!
8
2
%
!
9
5
!
8
2
%
!
7
6
!
!
!
6
7
%
!
3
7
%
!
2
7
"4
6
%
)!
†
!I
n
fo
rm
a
ti
o
n
!o
n
ly
!a
v
a
il
a
b
le
!f
o
r!
3
2
0
!p
a
ti
e
n
ts
.!
*
!T
h
is
!o
n
ly
!i
n
cl
u
d
e
s!
th
o
se
!2
5
0
!p
a
ti
e
n
ts
!t
re
a
te
d
!w
it
h
!c
u
ra
ti
v
e
!i
n
te
n
t.
!
*
*
!C
R
!o
n
ly
!a
v
a
il
a
b
le
!f
o
r!
2
4
7
!p
a
ti
e
n
ts
.!
*
*
*
!S
ta
tu
s!
u
n
a
v
a
il
a
b
le
!f
o
r!
1
6
!p
a
ti
e
n
ts
.!
*
*
*
*
!O
S
!i
n
fo
rm
a
ti
o
n
!a
v
a
il
a
b
le
!f
o
r!
2
3
4
!p
a
ti
e
n
ts
!d
u
e
!t
o
!m
is
si
n
g
!d
a
ta
.!
‡
!T
h
is
!k
a
ry
o
ty
p
e
!w
a
s!
e
xp
re
ss
e
d
!i
n
!c
o
n
ju
n
ct
io
n
!w
it
h
!t
h
e
!t
(8
;1
4
)!
in
!3
!p
a
ti
e
n
ts
!
a
!H
ig
h
!h
y
p
e
rd
ip
lo
id
y
!(
5
1
"6
5
!c
h
ro
m
o
so
m
e
s)
.!
b
!L
o
w
!h
y
p
e
rd
ip
lo
id
y
!(
3
0
"3
9
!c
h
ro
m
o
so
m
e
s)
!/
!N
e
a
r!
tr
ip
lo
id
y
!(
6
0
"7
8
!c
h
ro
m
o
so
m
e
s)
.!
c !
C
o
m
p
le
x!
k
a
ry
o
ty
p
e
!d
e
fi
n
e
d
!a
s!
fi
v
e
!o
r!
m
o
re
!c
h
ro
m
o
so
m
a
l!
a
b
n
o
rm
a
li
ti
e
s!
in
!t
h
e
!a
b
se
n
ce
!o
f!
a
n
!e
st
a
b
li
sh
e
d
!c
y
to
g
e
n
e
ti
c!
su
b
g
ro
u
p
.!
d
!2
0
!o
r!
m
o
re
!n
o
rm
a
l!
m
e
ta
p
h
a
se
s!
in
!t
h
e
!a
b
se
n
ce
!o
f!
a
n
y
!c
lo
n
a
l!
ch
ro
m
o
so
m
a
l!
a
b
n
o
rm
a
li
ty
.!
T
a
b
le
 3
: 
In
ci
d
en
ce
 o
f 
m
a
jo
r 
ch
ro
m
o
so
m
a
l 
a
b
n
o
rm
a
li
ti
es
 o
th
er
 t
h
a
n
 t
(9
;2
2
) 
in
 a
d
u
lt
 A
L
L
 o
b
se
rv
ed
 i
n
 t
h
is
 s
tu
d
y
 c
o
m
p
a
re
d
 t
o
 p
re
v
io
u
sl
y
 p
u
b
li
sh
ed
 c
li
n
ic
a
l 
tr
ia
ls
. 
S
tu
d
y
R
ef
er
en
c
e
N
o
.
p
at
ie
n
ts
 
te
st
ed
 
t(
9
;2
2
) 
%
 
t(
4
;1
1
) 
%
 
t(
1
;1
9
) 
%
 
t(
8
;1
4
) 
%
 
t(
1
4
;1
8
)
%
H
eH
a  
%
 
H
o
T
rb
 %
 
C
o
m
p
le
x
c
%
N
o
rm
al
d
%
T
h
is
 s
tu
d
y
 (
1
5
-5
9
 
y
ea
r 
o
ld
s 
o
n
ly
) 
N
A
2
3
6
1
4
%
6
%
4
%
4
%
1
%
9
%
2
%
4
%
2
9
%
M
R
C
 U
K
A
L
L
X
A
 
1
7
3
5
0
1
1
%
3
%
3
%
N
A
N
A
8
%
N
A
N
A
3
4
%
U
K
A
L
L
X
II
/E
C
O
G
2
9
9
3
2
1
3
7
3
1
9
%
4
%
2
%
1
%
N
A
6
%
2
%
3
%
1
4
%
C
A
L
G
B
2
2
2
5
6
2
6
%
5
%
N
A
N
A
N
A
N
A
N
A
N
A
2
5
%
G
IM
E
M
A
 0
4
9
6
 
2
0
3
8
6
2
6
%
7
%
2
%
N
A
N
A
N
A
N
A
N
A
2
6
%
S
W
O
G
 9
4
0
0
 
3
1
4
0
2
6
%
5
%
5
%
N
A
N
A
N
A
N
A
N
A
2
2
%
G
F
C
H
2
1
4
4
3
2
9
%
4
%
3
%
5
%
N
A
7
%
N
A
N
A
1
5
%
N
A
, 
N
o
t 
av
ai
la
b
le
. 
a
!H
ig
h
!h
y
p
e
rd
ip
lo
id
y
!(
5
1
"6
5
!c
h
ro
m
o
so
m
e
s)
.!
b
!L
o
w
!h
y
p
e
rd
ip
lo
id
y
!(
3
0
"3
9
!c
h
ro
m
o
so
m
e
s)
!/
!N
e
a
r!
tr
ip
lo
id
y
!(
6
0
"7
8
!c
h
ro
m
o
so
m
e
s)
.!
c !
C
o
m
p
le
x!
k
a
ry
o
ty
p
e
!d
e
fi
n
e
d
!a
s!
fi
v
e
!o
r!
m
o
re
!c
h
ro
m
o
so
m
a
l!
a
b
n
o
rm
a
li
ti
e
s!
in
!t
h
e
!a
b
se
n
ce
!o
f!
a
n
!e
st
a
b
li
sh
e
d
!c
y
to
g
e
n
e
ti
c!
su
b
g
ro
u
p
.!
d
!2
0
!o
r!
m
o
re
!n
o
rm
a
l!
m
e
ta
p
h
a
se
s!
in
!t
h
e
!a
b
se
n
ce
!o
f!
a
n
y
!c
lo
n
a
l!
ch
ro
m
o
so
m
a
l!
a
b
n
o
rm
a
li
ty
.!
T
a
b
le
 4
: 
T
h
e 
in
ci
d
en
ce
 o
f 
t(
9
;2
2
) 
in
 a
d
u
lt
 A
L
L
 i
n
 d
if
fe
re
n
t 
st
u
d
ie
s 
b
y
 a
g
e.
 
S
tu
d
y
R
ef
er
en
ce
N
o
.
p
at
ie
n
ts
 
te
st
ed
 
t(
9
;2
2
)
n
 (
%
) 
D
et
ec
ti
o
n
 M
et
h
o
d
 
A
g
e 
R
an
g
e 
(y
rs
)
M
ea
n
 A
g
e 
(y
rs
) 
<
2
0
y
ea
rs
n
 (
%
) 
<
3
0
 y
ea
rs
 
n
 (
%
) 
M
R
C
U
K
A
L
L
X
A
 
1
7
3
5
0
4
0
 (
1
1
%
) 
C
y
to
g
en
et
ic
s
1
5
-6
0
+
N
A
1
1
5
 (
3
3
%
) 
1
8
6
 (
5
3
%
) 
T
h
is
 s
tu
d
y
 
N
A
2
3
6
3
6
 (
1
5
%
) 
C
y
to
g
en
et
ic
s,
 (
p
lu
s 
so
m
e 
F
IS
H
 a
n
d
 R
T
-
P
C
R
1
5
-9
1
4
5
4
2
 (
1
8
%
) 
7
7
 (
3
3
%
) 
U
K
A
L
L
X
II
 
2
8
7
2
1
4
2
 (
1
6
%
) 
C
y
to
g
en
et
ic
s,
 F
IS
H
 a
n
d
 
R
T
-P
C
R
1
5
-5
5
3
1
2
0
7
 (
2
4
%
) 
4
5
3
 (
5
2
%
) 
E
C
O
G
2
9
9
3
2
5
0
1
1
2
5
 (
2
5
%
) 
C
y
to
g
en
et
ic
s,
 F
IS
H
 a
n
d
 
R
T
-P
C
R
1
5
-6
5
3
6
6
1
 (
1
2
%
) 
1
9
0
 (
3
8
%
) 
C
A
L
G
B
2
2
2
5
6
6
7
 (
2
6
%
) 
C
y
to
g
en
et
ic
s
1
5
-6
0
+
3
3
N
A
1
0
9
(4
3
%
)
G
IM
E
M
A
 0
4
9
6
 
2
0
3
8
6
1
0
2
 (
2
6
%
) 
C
y
to
g
en
et
ic
s 
an
d
 R
T
-
P
C
R
1
5
-6
0
3
1
N
A
1
4
8
 (
4
6
%
) 
S
W
O
G
 9
4
0
0
 
3
1
4
0
3
6
 (
2
6
%
) 
C
y
to
g
en
et
ic
s 
an
d
 R
T
-
P
C
R
1
5
-6
5
3
2
N
A
8
6
 (
4
3
%
) 
B
as
ed
 
o
n
 a
ll
 2
0
0
 p
at
ie
n
ts
 
G
F
C
H
2
1
4
4
3
1
2
7
 (
2
9
%
) 
C
y
to
g
en
et
ic
s
1
5
-6
0
+
3
7
9
0
 (
2
0
%
) 
1
6
9
 (
3
8
%
) 
G
M
A
L
L
1
9
2
4
9
8
9
0
4
 (
3
6
%
) 
R
T
-P
C
R
1
5
-7
4
N
A
<
2
5
 y
rs
 
4
8
1
 (
1
9
%
) 
<
3
5
 y
rs
 
9
0
2
 (
3
6
%
) 
F
ig
.1
.!
!!
N
u
m
b
e
r!
o
f!
p
a
ti
e
n
ts
!d
ia
g
n
o
se
d
!i
n
!t
h
e
!N
o
rt
h
!E
a
st
!o
f!
E
n
g
la
n
d
!w
it
h
!a
d
u
lt
!a
cu
te
!l
y
m
p
h
o
b
la
st
ic
!!
!l
e
u
k
a
e
m
ia
!b
e
tw
e
e
n
!1
9
8
3
!a
n
d
!2
0
0
1
!s
u
b
"d
iv
id
e
d
!b
y
!c
y
to
g
e
n
e
ti
c!
a
n
a
ly
si
s!
a
t!
d
ia
g
n
o
si
s!
!
05
1
0
1
5
2
0
2
5
3
0
1
9
8
3
1
9
8
4
1
9
8
5
1
9
8
6
1
9
8
7
1
9
8
8
1
9
8
9
1
9
9
0
1
9
9
1
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
Y
e
a
r 
o
f 
d
ia
g
n
o
s
is
No. of cases
N
o
 C
yt
o
g
e
n
e
ti
c
s
C
yt
o
g
e
n
e
ti
c
s
 A
tt
e
m
p
te
d
F
ig
.2
.!
!!
A
g
e
"s
p
e
ci
fi
c!
in
ci
d
e
n
ce
!o
f!
a
d
u
lt
s!
w
it
h
!a
cu
te
!l
y
m
p
h
o
b
la
st
ic
!l
e
u
k
a
e
m
ia
!(
A
LL
)!
in
!t
h
e
!N
o
rt
h
!E
a
st
!o
f!
E
n
g
la
n
d
!b
y
!s
e
x
.!
! !
!
! ! !
F
ig
.3
.!
O
v
e
ra
ll
!s
u
rv
iv
a
l!
o
f!
a
d
u
lt
s!
w
it
h
!a
cu
te
!l
y
m
p
h
o
b
la
st
ic
!l
e
u
k
a
e
m
ia
!(
A
LL
)!
b
y
!a
g
e
!a
t!
d
ia
g
n
o
si
s!
!
! ! !
!F
ig
!4
.!
O
v
e
ra
ll
!s
u
rv
iv
a
l!
o
f!
a
d
u
lt
s!
w
it
h
!a
cu
te
!l
y
m
p
h
o
b
la
st
ic
!l
e
u
k
a
e
m
ia
!(
A
LL
)!
b
y
!c
y
to
g
e
n
e
ti
c!
ri
sk
!g
ro
u
p
!
! ! !
